Plasma exchange and rituximab treatments in primary membranous nephropathy combined with crescentic glomerulonephritis
Open Access
- 1 May 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 98 (18) , e15303
Abstract
Rationale: Crescent formation is rare in primary membranous nephropathy (MN). Anti-phospholipase A2 receptor (PLA2R) antibodies are detectable in these patients. The mechanism and treatments are unknown. Patient concerns: A 72-year-old female patient who presented with nephrotic syndrome, hematuria, and rapidly progressive kidney dysfunction. Diagnoses: Kidney biopsy was performed and the diagnosis was MN in combination with crescentic glomerulonephritis. Circulating anti-PLA2R IgG3 and IgG4 were detected of high level. Interventions: The patient received plasma exchange and rituximab besides corticosteroids. Outcomes: The patient achieved complete remission of proteinuria and recovery of kidney function after the clearance of anti-PLA2R antibodies. Lesson: This case suggests a pathogenic role of anti-PLA2R antibodies in the mechanism of crescent formation in MN, which may need intensive therapy to eliminate the antibodies quickly.Keywords
This publication has 21 references indexed in Scilit:
- Primary Membranous NephropathyClinical Journal of the American Society of Nephrology, 2017
- Crescentic glomerulonephritis and membranous nephropathy: a rare coexistenceInternational Urology and Nephrology, 2015
- Pathophysiological advances in membranous nephropathy: time for a shift in patient's careThe Lancet, 2015
- Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathyKidney International, 2013
- Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous NephropathyJournal of the American Society of Nephrology, 2012
- The pathogenesis of membranous nephropathyCurrent Opinion in Nephrology and Hypertension, 2012
- Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous NephropathyJournal of the American Society of Nephrology, 2011
- Antigen Identification in Membranous Nephropathy Moves toward Targeted Monitoring and New TherapyJournal of the American Society of Nephrology, 2010
- M-Type Phospholipase A2Receptor as Target Antigen in Idiopathic Membranous NephropathyNew England Journal of Medicine, 2009
- Rapidly Progressive Glomerulonephritis: Classification, Pathogenetic Mechanisms, and TherapyAmerican Journal of Kidney Diseases, 1988